Table GPS-17. Lifetime prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population. Last survey available for each Member State (from 2000 onwards)

Country		Geographical Area	Year	Reference	Age range (15–24)	Sample size (15–24)	Cannabis (%)	Cocaine (%) (1)	Amphetamines (%) (2)	Ecstasy (%) (3)	LSD (%)
Belgium		National	2004	(6)	15–24		22.3
Bulgaria		National	2005	(1)	18–24	173	13.5	3.8	4.4	3.8	2.7
Czech Republic		National	2004	(2)	18–24	586	43.9	2.1	4.9	18.7	3.7
Denmark		National	2005	(4)	16–24	1434	44.2	8	11.2	5.5	1.8
Germany		National	2006	(7)	18–24	1868	39	4	5.1	5.3	2.1
Estonia		National	2003	(2)	15–24	329
Ireland		National	2006–07	(5)	15–24		24.8	7	3.2	6.5	1
Greece		National (except Aegean and Ionian Islands)	2004	(3)	15–24	1 785	9	0.6	0.2	0.4	0.5
Spain		National	2005–06	(6)	15–24	8188	38.9	8.7	4.9	6.9
France		National	2005	(6)	15–24	4662	42	2.5	0.8	3	0.8
Italy		National	2005	(3)	15–24	9006	32.6	5.7	1.7	2.5	3.5
Cyprus		National	2006	(1)	15–24	969	6.9	1.4	0.9	2.1	0.9
Latvia		National	2003	(1)	15–24		22.9	1.4	6	6.2	2.8
Lithuania		National	2004	(1)	15–24	923	15.7	0.7	2.6	2.6	0.7
Hungary		National	2003	(2)	18–24	943	25.3	1.4	5.9	7.9	4.2
Malta		National	2001	(1)	18–24	287	4.9	1.1	1.1	1.7	1.6
Netherlands		National	2005	(3)	15–24		28.3	2.8	2	5.1	0.7
Austria		National	2004	(1)	15–24	959	29.7	2.9	3.7	5.2	1.8
Poland		National	2006	(2)	15–24	1135	17.3	1.1	4.8	2.3	1.7
Portugal		National	2007	(2)	15–24	2211	15.1	1.4	0.8	2.1	0.6
Romania		National	2004	(1)	15–24		2.7	0.4	0.3	0.8	0
Slovakia		National	2006	(6)	15–24	287	31.3	2.5	3.6	9.9
Finland		National	2006	(7)	15–24	654	19	1.3	3.9	3.3	1
Sweden		National	2006	(7)	16–24	7014	15.4
UK		England and Wales	2006–07	(10)	16–24	5749	39.5	11.2	11.2	10.3	3.2
UK		Northern Ireland	2005	(12)	16–24		28.9	6.3	8.6	10.7	1.3
UK		Scotland	2006	(15)	16–24	426	48.9	15.6	15.6	14.8	5
UK		United Kingdom	2004	(13)			40.4	9	12.3	11	4.5
Norway		National	2004	(2)	15–24	645	23.4	3.4	5.3	3.4	0.8

Notes:

 (1) Cocaine, any form. 

 (2) For Belgium National 2001 and for Metropolitan France 1995: amphetamine and ecstasy, for Denmark National 1994: hard drugs. 

 (3) For Spain: ecstasy and other designer drugs. 

 This table aims to present an overview of national surveys. Exceptionally, some relevant regional surveys are presented. Some city surveys reported by countries were not included as they tend to produce higher prevalence estimates which are not comparable with estimates for whole countries (or large regions with both urban and rural areas). Athens was included as reference point for the 1993 survey.  

 In surveys with small sample sizes results should be interpreted with caution. 

 Countries were asked to report results using, as far as possible, EMCDDA standard age groups (all adults: 15-64, young adults: 15-34). In countries where age ranges are more restrictive, prevalence estimates tend to be slightly higher. Some countries have recalculated their prevalence figures using the EMCDDA standard age groups. 

 For methods and definitions on population surveys in general, see General population surveys of drug use – methods and definitions. 

 For methods of each survey presented in this table, see Table GPS-1 part (ii).  

 See also 'General notes for interpreting data' on the Explanatory notes and help page. 

                        

Sources:

 See Table GPS-0. 

• Download this data in Excel (.xls) format

(see the help page for information about formats etc.)